Conference Coverage

Sapien M3 mitral valve replacement data reported for first 10 patients


 

REPORTING FROM CRT 2018


In this series of patients, one stroke occurred 2 days after the procedure, but there were no deaths in the initial 30-day follow-up, according to Dr. Webb. Although he noted that the procedure time in the first case was 4 hours, the procedure times became shorter with experience and the second-to-last and last cases took 2.5 and 1.3 hours, respectively.

Howard C. Herrmann, MD, director of the interventional cardiology program at the University of Pennsylvania, Philadelphia, and a panelist on the symposium where these data were presented, called the results “exciting.” However, he also noted that “this is the first time that any us have had a look at this device,” so more data will be needed to understand its clinical potential.

Edwards Lifesciences sponsored this study. Dr. Webb reported financial relationships with Abbott Vascular, Edwards Lifesciences, Essential Medical, and Vivitro.

Pages

Recommended Reading

Meta-analysis: Thin struts equal better outcomes for drug-eluting stents
MDedge Cardiology
Impaired kidney function no problem for dabigatran reversal
MDedge Cardiology
VIDEO: Meeting stroke screening demand will require systems’ reorganization
MDedge Cardiology
Cost-effectiveness battle: FFR vs. iFR in DEFINE-FLAIR trial
MDedge Cardiology
Endovascular interventions associated with large benefits in peripheral artery disease
MDedge Cardiology
Interventionalists skeptical about public reporting of PCI
MDedge Cardiology
CABANA: AF ablation ties drug management, with an asterisk for crossovers
MDedge Cardiology
Device-related thrombus associated with ischemic events
MDedge Cardiology
Design limitations may have compromised DVT intervention trial
MDedge Cardiology
For in-stent restenosis, everolimus-eluting stents topped drug-eluting balloons
MDedge Cardiology